SCHEMBL19610322

SCHEMBL19610322

CC(C)c1c[nH]c(-c2cc3sccc3n2C)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 12/20 0.58
MAPT P10636 4/20 0.36
NPC1 O15118 4/20 0.34
RAB9A P51151 4/20 0.34
TSHR P16473 4/20 0.34
RCOR1 Q9UKL0 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
TP53 P04637 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
PIM1 P11309 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
LMNA P02545 1/20 0.34
ALOX15 P16050 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19610331 0.82 KDM1A (0.52) KDM1AMAPTNPC1RAB9ATSHR
SCHEMBL19610168 0.80 KDM1A (0.61) KDM1ARAB9ATSHRALOX15
SCHEMBL19610374 0.77 KDM1A (0.60) KDM1ANPC1RAB9ATSHRSMN1; SMN2
SCHEMBL19610291 0.77 KDM1A (0.62) KDM1AMAPTNPC1RAB9AALOX15
SCHEMBL19610239 0.77 KDM1A (0.60) KDM1AMAPTNPC1RAB9ATSHR
SCHEMBL19610181 0.76 KDM1A (0.47) KDM1ATSHRRCOR1NPSR1
SCHEMBL19610283 0.75 KDM1A (0.61) KDM1ANPC1RAB9ATSHRSMN1; SMN2
SCHEMBL20985143 0.73 KDM1A (0.49) KDM1AMAPTNPC1RAB9AALOX15
SCHEMBL19610440 0.72 KDM1A (0.56) KDM1AMAPTNPC1RAB9ATSHR
SCHEMBL19610307 0.71 KDM1A (0.58) KDM1AMAPTNPC1RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109641918-B Imidazoles as inhibitors of histone demethylases 欧洲肿瘤研究所有限责任公司 2021-12-21 CN claimed
EP-3458460-B1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS ST EUROPEO DI ONCOLOGIA S R L (IT) 2020-12-09 EP claimed
US-10562914-B2 Imidazoles as histone demethylase inhibitors ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2020-02-18 US claimed
US-20190152987-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2019-05-23 US claimed
EP-3458460-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS Istituto Europeo di Oncologia S.r.l. (IT) 2019-03-27 EP claimed
WO-2017198780-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2017-11-23 WO claimed
EP-3246330-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS Istituto Europeo di Oncologia S.r.l. (IT) 2017-11-22 EP claimed
CN-109641918-B Imidazoles as inhibitors of histone demethylases 欧洲肿瘤研究所有限责任公司 2021-12-21 CN disclosed
US-10961255-B2 Imidazoles as histone demethylase inhibitors ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2021-03-30 US disclosed
US-10961255-B2 Imidazoles as histone demethylase inhibitors ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2021-03-30 US disclosed
EP-3458460-B1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS ST EUROPEO DI ONCOLOGIA S R L (IT) 2020-12-09 EP disclosed
US-20200299303-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2020-09-24 US disclosed
US-20200299303-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2020-09-24 US disclosed
US-10562914-B2 Imidazoles as histone demethylase inhibitors ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2020-02-18 US disclosed
US-10562914-B2 Imidazoles as histone demethylase inhibitors ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2020-02-18 US disclosed
US-20190152987-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2019-05-23 US disclosed
US-20190152987-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2019-05-23 US disclosed
EP-3458460-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS Istituto Europeo di Oncologia S.r.l. (IT) 2019-03-27 EP disclosed
WO-2017198780-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2017-11-23 WO disclosed
EP-3246330-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS Istituto Europeo di Oncologia S.r.l. (IT) 2017-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190152987-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, DOT1L KDM1A 2/4885MAPT 2707/4885NPC1 3364/4885
US-20200299303-A1 IMIDAZOLES AS HISTONE DEMETHYLASE INHIBITORS DOT1L, KDM1B, KDM1A KDM1A 3/4885MAPT 2180/4885NPC1 3295/4885
US-10562914-B2 Imidazoles as histone demethylase inhibitors KDM1B, KDM1A, DOT1L KDM1A 2/4885MAPT 2707/4885NPC1 3364/4885
US-10961255-B2 Imidazoles as histone demethylase inhibitors DOT1L, KDM1B, KDM1A KDM1A 3/4885MAPT 2180/4885NPC1 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.